Publication | Closed Access
Gefitinib and Afatinib Show Potential Efficacy for Fanconi Anemia–Related Head and Neck Cancer
45
Citations
29
References
2020
Year
Our data present a complete preclinical analysis and promising therapeutic line of the first FDA/EMA-approved anticancer drugs exerting cancer-specific toxicity for HNSCC in patients with Fanconi anemia.
| Year | Citations | |
|---|---|---|
Page 1
Page 1